Annette Langer-Gould to Immunologic Factors
This is a "connection" page, showing publications Annette Langer-Gould has written about Immunologic Factors.
Connection Strength
5.285
-
Racial Inequities, Multiple Sclerosis, and Implementation of a Novel Treatment Algorithm at the Health System Level. Neurology. 2025 May 27; 104(10):e213607.
Score: 0.951
-
Multiple sclerosis, rituximab, and COVID-19. Ann Clin Transl Neurol. 2021 04; 8(4):938-943.
Score: 0.718
-
Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies. Neurol Neuroimmunol Neuroinflamm. 2021 03; 8(2).
Score: 0.711
-
Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinflamm. 2020 07; 7(4).
Score: 0.674
-
Pregnancy and Family Planning in Multiple Sclerosis. Continuum (Minneap Minn). 2019 Jun; 25(3):773-792.
Score: 0.632
-
Immunomodulatory agents and risk of postpartum multiple sclerosis relapses. Perm J. 2014; 18(1):9-13.
Score: 0.434
-
Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden. JAMA Netw Open. 2021 12 01; 4(12):e2136697.
Score: 0.188
-
Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Neurol Neuroimmunol Neuroinflamm. 2020 11; 7(6).
Score: 0.174
-
Safety of potential breast milk exposure to IFN-ß or glatiramer acetate: One-year infant outcomes. Neurol Neuroimmunol Neuroinflamm. 2020 07; 7(4).
Score: 0.169
-
Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2020 07 02; 7(4).
Score: 0.168
-
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Ann Neurol. 2020 05; 87(5):688-699.
Score: 0.167
-
Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler. 2016 05; 22(6):801-9.
Score: 0.126
-
Absence of neuromyelitis optica IgG antibody in an active relapsing-remitting multiple sclerosis population. J Neuroophthalmol. 2009 Jun; 29(2):104-6.
Score: 0.079
-
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 Feb 14; 358(7):676-88.
Score: 0.072
-
Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis. Mult Scler. 2012 Mar; 18(3):377-8.
Score: 0.023